The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
Roger Henriksson
Consultant or Advisory Role - Roche
Honoraria - Roche
Andrew Bottomley
No relevant relationships to disclose
Warren Mason
Consultant or Advisory Role - Roche
Frank Saran
Consultant or Advisory Role - Roche
Wolfgang Wick
Consultant or Advisory Role - Lilly; Roche
Honoraria - MSD; Roche
Research Funding - Apogenix; Boehringer Ingelheim; MSD
Ryo Nishikawa
Consultant or Advisory Role - Roche
Timothy Francis Cloughesy
Consultant or Advisory Role - Apogenics; Celgene; Genentech; Merck; Merck Serono; NewGen Therapeutics; Roche; Tocagen
Antoine F Carpentier
Consultant or Advisory Role - Roche
Honoraria - Roche
Khe Hoang-Xuan
Consultant or Advisory Role - Roche (U)
Petr Kavan
No relevant relationships to disclose
Dana Cernea
No relevant relationships to disclose
Alba Ariela Brandes
No relevant relationships to disclose
Magalie Hilton
Employment or Leadership Position - Roche
Ana Maria Abajo Guijarro
Employment or Leadership Position - Roche
Arliene Ravelo
Employment or Leadership Position - Roche
Oliver L. Chinot
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; MSD; Roche
Research Funding - Merck; Roche